Craftport Cannabis Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Craftport Cannabis's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 49.5% per year.
Belangrijke informatie
-18.4%
Groei van de winst
8.8%
Groei van de winst per aandeel
| Pharmaceuticals Groei van de industrie | 23.1% |
| Inkomstengroei | 49.5% |
| Rendement op eigen vermogen | n/a |
| Nettomarge | -4,454.1% |
| Laatste winstupdate | 30 Sep 2022 |
Recente prestatie-updates uit het verleden
Opbrengsten en kosten
Hoe Craftport Cannabis geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -8 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 1 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -10 | 3 | 0 |
| 30 Sep 21 | 1 | -13 | 3 | 0 |
| 30 Jun 21 | 1 | -12 | 3 | 0 |
| 31 Mar 21 | 1 | -10 | 3 | 0 |
| 31 Dec 20 | 1 | -10 | 3 | 0 |
| 30 Sep 20 | 1 | -1 | 4 | 0 |
| 30 Jun 20 | 0 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 5 | 0 |
| 31 Dec 19 | 0 | -4 | 5 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -7 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Kwaliteitswinsten: CFT is currently unprofitable.
Groeiende winstmarge: CFT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: CFT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Versnelling van de groei: Unable to compare CFT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: CFT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Rendement op eigen vermogen
Hoge ROE: CFT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.